Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer’s Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study - 21/11/24
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background/Objectives |
depressive symptoms are common in Alzheimer’s disease(AD). Aim of the study was to investigate the efficacy of vortioxetine compared with other conventional antidepressants on cognitive functions in AD patients with depressive symptoms
Design |
Prospective, randomized, 12 month, parallel-group study.
Setting |
All participants were evaluated on-site at Neurodegenerative Disorders Unit, ASP2 Caltanissetta(Italy).
Participants |
108 (71 female, 37 male) AD patients with depression(mean age 76.7± 4.3).
Intervention |
Randomized subjects received vortioxetine, 15 mg/day (n=36) or other common antidepressants(n=72).
Measures |
primary outcome was change from baseline in the MMSE; secondary outcomes were change in Attentive Matrices, Raven Coloured Progressive Matrices, Digit Span, HAM-D and Cornell scale.
Results |
Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores. The most commonly reported adverse events were nausea and headache for votioxetine; nausea in the control group.
Conclusions |
Vortioxetine had a beneficial effect on cognition and mood in elderly AD patients and was safe and well tolerated.
El texto completo de este artículo está disponible en PDF.Key words : Vortioxetine, Alzheimer’s disease, antidepressants, depressive symptoms
Esquema
Vol 6 - N° 3
P. 192-197 - juillet 2019 Regresar al número
Artículo precedente
- Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer’s Disease Patients in the General Population
- O. Uspenskaya-Cadoz, C. Alamuri, L. Wang, M. Yang, Sam Khinda, Y. Nigmatullina, T. Cao, N. Kayal, M. O’Keefe, C. Rubel
- Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018
- B. Vellas, L.J. Bain, J. Touchon, P.S. Aisen
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.